Ksilink's programs are subject to financial incentives. Public co-fi-nancement can account for up to 50% of development costs, decreasing the burden for clients, with no strings attached.
Ksilink can engage as a program specific co-investor. Beyond public co-financement, Ksilink’s risk-shar-ing engagement can effectively reduce cash-in-hand needs for the client
Ksilink fosters innovation by assigning IP-rights to the client. In cases of risk-shar-ing engagement, fair compensation for Ksilink can be backloaded for Biotech and Academic clients